ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Ernexa Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.98−0.11 (-5.26%)
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$28.52 (−93.51%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.34M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.73
- Dividend yield
- –
- Free cash flow yield
- -301.15%
Fundamentals
- Net income
- -$12.26M
- EPS, diluted
- -$2.24
- Free cash flow
- -$7.05M
- Book value per share
- $2.70
- Diluted shares
- 1M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$13.78M
Net income
-$12.26M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months